Please login to the form below

Not currently logged in
Email:
Password:

hepatitis B

This page shows the latest hepatitis B news and features for those working in and with pharma, biotech and healthcare.

Gilead claims FDA okay for Descovy as second PrEP option

Gilead claims FDA okay for Descovy as second PrEP option

warning that patients with HIV and hepatitis B virus (HBV) co-infections can experience exacerbation when stopping treatment with the drug.

Latest news

  • Arbutus hit hard as new hep B drug fails on safety Arbutus hit hard as new hep B drug fails on safety

    Shares have fallen sharply since company reported results. Shares in Arbutus have fallen sharply after the company reported that its hepatitis B virus (HBV) drug AB-506 has been abandoned. ... two cases of acute hepatitis seen in healthy volunteers that

  • UK bans some drug exports to preserve NHS stocks UK bans some drug exports to preserve NHS stocks

    It applies mainly to hormone replacement therapies but also includes all adrenaline pens, hepatitis B vaccines and the influenza drug oseltamivir, sold by Roche as Tamiflu, amongst other drugs.

  • GSK to develop Ionis hepatitis B drugs GSK to develop Ionis hepatitis B drugs

    GlaxoSmithKline has exercised its option to license Ionis' antisense medicines for chronic hepatitis B virus (CHB) infection, boosting its presence in virology. ... Gilead is once again setting the pace, and already has a ‘hepatitis B cure research

  • Gilead continues its exec clear-out, licenses antivirals from Novartis Gilead continues its exec clear-out, licenses antivirals from Novartis

    Most significantly, John McHutchison, its head of research and development who oversaw the development of its blockbuster hepatitis C franchise, as well as hepatitis B treatments and the company’s expansion ... slump in its hepatitis C revenues.

  • First-in-class hepatitis B/D drug raises cure hope First-in-class hepatitis B/D drug raises cure hope

    Those taking the regimen saw virus levels decline. German biotech Myr Pharma has reported positive phase 2b trial data with bulevirtide in patients with chronic hepatitis B and D, driving the ... A new generation of directly-acting antivirals for

More from news
Approximately 8 fully matching, plus 83 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    hepatitis B virus (HBV). Strategic. collaboration ‐. development. $445m. Innate Pharma/. ... Manufacture and supply of CAR‐T cell therapy, Kymriah, for B‐cell acute lymphoblastic leukaemia.

  • No incentive for a cure No incentive for a cure

    Hepatitis C virus treatments like Maviret from AbbVie, which cures people with hard-to-treat genotype 3 after an 8  to 12-week course. ... This is the route the NHS in the UK has taken with innovative hepatitis C treatments; it will only pay for the

  • Pharma deals in April 2015 Pharma deals in April 2015

    its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers. ... These are key markets for this product as more than 75% of all HCC cases occur in the APAC region, largely in association with

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Corporate acquisition. 545. Cytos Biotechnology/ OnCore. Access to virus like particle (VLP) platform for the treatment and prevention of hepatitis B with an option to other viral diseases.

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    153. NeuroVive / OnCore. Licence and collaboration. NVP018 an oral sangamide-based 2nd generation cyclophilin inhibitor for hepatitis B.

More from intelligence
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • UK vs US: what makes a successful immunisation programme?

    My challenge started when my daughter Anna was born. The Hepatitis B vaccine is given at birth in the US, and at the time, this was not a part of the ... The Meningitis B vaccine is unique to the UK and since we live in the UK that was easy to get.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics